NCT03614234View on ClinicalTrials.gov

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

March 28, 2026

Conditions
Fabry Disease
Interventions
DRUG

pegunigalsidase alfa

Recombinant human alpha galactosidase A

Trial Locations (14)

2100

Medical Endocrinology PE 2132, Rigshospitalet, Copenhagen

2650

UZ Antwerpen, Edegem

5021

Helse Bergen HF Haukeland Universitetssykehus, Bergen

22030

O & O Alpan, Fairfax

30307

Emory University School of Medicine, Atlanta

35233

UAB Medicine, Birmingham

49525

Infusion Associates, Grand Rapids

52242

University of Iowa Hospitals and Clinica, Iowa City

75235

Renal Disease Research Institute, LLC, Dallas

80131

"Azienda Ospedaliera Universitaria Federico II", Napoli

84112

University of Utah Hospitals & Clinics, Salt Lake City

128 08

Fakultní poliklinika Všeobecné fakultní nemocnice v Praze, Prague

CB2 0QQ

Addenbrooke's Hospital, Cambridge

Unknown

The Royal Free Hospital, London

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY